Protection from infection.

See what's possible

CUVITRU was studied in 77 people with primary immunodeficiency (PI) ≥2 years of age, with the main goal of measuring how many acute serious bacterial infections (ASBIs) were experienced over the course of 1 year. ASBIs are short-term but serious infections that require immediate medical care. [For an immunoglobulin (Ig) treatment to be effective, the rate of ASBIs must be <1 per year. On average, people taking CUVITRU experienced 0.012 per year, which is significantly less.]

See what's possible

Treatment on my terms.

CUVITRU [Immune Globulin Subcutaneous (Human)] 20% is a primary immunodeficiency treatment that offers consistent Ig levels in between infusions, protection from infection, and a flexible treatment schedule.¹

You and your doctor can create a treatment plan based on your preference–faster infusions or fewer needlesticks.¹

See what's possible

My PI treatment
on my time.

Read about the protection from infection you deserve and flexible infusion options of CUVITRU.¹

Get CUVITRU facts

With Takeda, I have an
ally to turn to.

Find more information about CUVITRU, including a guide for how to talk to your doctor about this subcutaneous immunoglobulin (SCIG) treatment.

Download. Watch. Explore.

There are people
just like me.

Learn how CUVITRU helped patients fight PI while getting back to things they enjoy because of CUVITRU's flexible administration.

Explore real stories

- Hadlie Jo, Actual patient with PI

- Julie, Actual patient with PI

- Walter, Actual patient with PI

CUVITRU [Prescribing Information]. Lexington, MA: Baxalta US Inc.

Protection from infection.

Treatment on my terms.

My PI treatment on my time.

With Takeda, I have an ally to turn to.

There are people just like me.

You are now leaving CUVITRU.com

For healthcare professionals only

You are now leaving CUVITRU.com

My PI treatment
on my time.

With Takeda, I have an
ally to turn to.

There are people
just like me.

You are now leaving
CUVITRU.com

For healthcare
professionals only

You are now leaving
CUVITRU.com